Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
The average 25(OH)D3 serum level at d0 was 39.8 ng/ml, which increased by 7.5 ng/ml at d1 and by further 6.6 ng/ml at d2.
Source: Epigenome-wide response to vitamin D3 bolus supplementation. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Chromatin and transcriptional dynamics underlying the immune-modulatory effects of vitamin D3 in vivo
Study design awaiting verification · Scientific Reports · 2025
Original publication title
Chromatin and transcriptional dynamics underlying the immune-modulatory effects of vitamin D3 in vivo
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Vitamin D3 is an essential micronutrient that supports innate immunity and modulates adaptive responses, with in vitro studies implicating epigenetic mechanisms. Yet, in vivo evidence for such regulation remains scarce. Here, we assessed genome-wide epigenomic and transcriptomic responses to vitamin D3 in a high responder from the VitDHiD repeated-measures, non-randomized interventional N-of-1 study, in which the participant received monthly oral boluses of 80,000 IU vitamin D3 over three months. Peripheral blood mononuclear cells (PBMCs) were collected at baseline (day 0) and at 24 and 48 h post-supplementation (days 1 and 2) for ATAC-seq and RNA-seq profiling.
ATAC-seq identified > 3,500 regions with increased chromatin accessibility, predominantly at promoters, indicating a strong epigenomic activation. Motif enrichment revealed immune-regulatory transcription factors, but not vitamin D receptor (VDR) motifs, suggesting indirect or cooperative modes of regulation. RNA-seq detected 380 vitamin D: responsive genes with time-dependent expression changes, including DUSP6 and FOS, enriched in pathways related to innate immunity and interferon signaling. Integrative analysis linked 306 differentially expressed genes to vitamin D: sensitive chromatin regions. Many of these overlap with VDR binding sites or promoters of neighboring non-target genes, suggesting potential long-range regulation.
Shared enhancers and promoters among neighboring genes indicated redundancy in regulatory architecture. Analysis of PBMCs from 13 participants in the VitDPAS non-randomized interventional cohort study, each receiving a single vitamin D3 bolus, confirmed the main findings from the N-of-1 study but also revealed pronounced inter-individual variability in epigenomic and transcriptomic responses. Together, these results provide in vivo evidence that vitamin D signaling directly and indirectly modulates chromatin accessibility and gene expression, emphasizing its role as an epigenetic regulator of immune function and supporting its potential in personalized nutrition and immune health strategies.
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-025-32831-z.
Authors’ abstract
Vitamin D3 is an essential micronutrient that supports innate immunity and modulates adaptive responses, with in vitro studies implicating epigenetic mechanisms. Yet, in vivo evidence for such regulation remains scarce. Here, we assessed genome-wide epigenomic and transcriptomic responses to vitamin D3 in a high responder from the VitDHiD repeated-measures, non-randomized interventional N-of-1 study, in which the participant received monthly oral boluses of 80,000 IU vitamin D3 over three months. Peripheral blood mononuclear cells (PBMCs) were collected at baseline (day 0) and at 24 and 48 h post-supplementation (days 1 and 2) for ATAC-seq and RNA-seq profiling.
ATAC-seq identified > 3,500 regions with increased chromatin accessibility, predominantly at promoters, indicating a strong epigenomic activation. Motif enrichment revealed immune-regulatory transcription factors, but not vitamin D receptor (VDR) motifs, suggesting indirect or cooperative modes of regulation. RNA-seq detected 380 vitamin D: responsive genes with time-dependent expression changes, including DUSP6 and FOS, enriched in pathways related to innate immunity and interferon signaling. Integrative analysis linked 306 differentially expressed genes to vitamin D: sensitive chromatin regions. Many of these overlap with VDR binding sites or promoters of neighboring non-target genes, suggesting potential long-range regulation.
Shared enhancers and promoters among neighboring genes indicated redundancy in regulatory architecture. Analysis of PBMCs from 13 participants in the VitDPAS non-randomized interventional cohort study, each receiving a single vitamin D3 bolus, confirmed the main findings from the N-of-1 study but also revealed pronounced inter-individual variability in epigenomic and transcriptomic responses. Together, these results provide in vivo evidence that vitamin D signaling directly and indirectly modulates chromatin accessibility and gene expression, emphasizing its role as an epigenetic regulator of immune function and supporting its potential in personalized nutrition and immune health strategies.
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-025-32831-z.
Publication and source details
Original title: Chromatin and transcriptional dynamics underlying the immune-modulatory effects of vitamin D3 in vivo
Maciej Rybiński; Ranjini Ghosh Dastidar; Natalia Zawrotna; Emilia Gospodarska; Carsten Carlberg
Scientific Reports · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/501100000780European Commission952601Carlberg Carsten https://doi.org/10.13039/501100004281Narodowe Centrum Nauki2023/49/B/NZ9/00402Carlberg CarstenRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T00:18:36.658547+00:00
DOI: 10.1038/s41598-025-32831-z · PMC12830676